5Vidrine DJ, Amick BC 3rd, Gritz ER, et al. Functional status and overall quality of life in a multiethnic HIV-posi- tive population [ J ]. AIDS Patient Care STDS, 2003, 17 (4) :187.
8Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents [J]. Ann Intern Med, 2002, 137(5 Pt 2):381-433.
9Hainaut M, Ducarme M, Schandene L, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children [J]. Pediatr Infect Dis J, 2003, 22(1):62-69.
10Hill A, Miralles D, Vangeneugden T, et al. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients? [J]. AIDS, 2007, 21(12):1651-1653.
2UNAIDS. Together we will end AIDS [ DB/OL [ 2013-3-25 ]. http ://wwwunaidsorg/en./resources/campaigns/togetherwewillen- daids/unaidsreport/.
3Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health, 2010, 15(2) : 251-258.
4Xia Wang, Xing Hui, Yuhua Ruan, et al. Effect of Viral Load and Drug Resistance on Mortality among Chinese HIV-Infected Pa- tients Receiving Antiretroviral Treatment. J Antiviral Antiretrovir, 2012, 4(3) : 60-65.
5Gsponer T, Petersen M, Egger M, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS, 2012, 26(1 ) : 57-65.
6Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, et al. High rate multiple drug resistances in HI-infected patients faihng non- nucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic), 2006, 5(4) : 152-156.
7Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis, 2008, 46(10) : 1589-1597.
8Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Op- tions for a second-line antiretroviral regimen for HIV type 1-infec- ted patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis, 2007, 44(3) : 447-452.
9Hosseinipour MC, van 0osterhout JJ, Weigel R, et al. The publichealth approach to identify antiretroviral therapy failure : high-level nucleoside reverse transcriptase inhibitor resistance among Malaw- ians failing first-line antiretroviral therapy. AIDS, 2009, 23 (9) : 1127-1134.
10Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretro- viral treatment switches and accumulation of HIV resistance muta- tions; two arguments for viral load monitoring in Mrica. J Acquir Immune Defic Syndr, 2011, 58 ( 1 ) : 23-31.
